
Pharmacally
Laromestrocel
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Laromestrocel
Health TidingsLongeveron Reports Fewer Cardiac Events in Infants With HLHSLongeveron’s Phase 2b ELPIS II trial found significantly fewer major adverse cardiac events with laromestrocel in infants with hypoplastic left heart syndrome.Fact-Checked
Clinical TrialsLongeveron Laromestrocel Misses ELPIS II HLHS EndpointLongeveron’s investigational cell therapy laromestrocel failed to improve right ventricular ejection fraction at 12 months in the Phase 2b ELPIS II trial in infants with hypoplastic left heart…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.